KR20010006589A - Agent for treating urination disorder - Google Patents

Abstract

PURPOSE: To obtain a therapeutic agent for dysuria improved in therapeutic effect by formulating a well-known therapeutic agent for dysuria containing dried extract of pumpkin seed as an active ingredient with other ingredient. CONSTITUTION: This therapeutic agent contains dried extract of pumpkin seed and isoflavone as active ingredients and the formulation ratio by weight of the dried extract of pumpkin and isoflavone is (99:1) to (80:20).

Description

Urination disorder medicine {AGENT FOR TREATING URINATION DISORDER}

The present invention relates to an agent for treating urination disorder, and more particularly, to an agent for treating urination disorder with improved therapeutic effect. Here, urination disorder treatment refers to urine that loses urine, besides reducing urinary frequency, reducing nocturnal polyuria, increasing urinary output and urinary output, eliminating urinary cleavage, eliminating difficulty in urination, and reducing residual urine and retention urine. Incontinence means treatment.

Background Art Dry extract of pumpkin seeds has been known as one of the treatments for urination disorders. Specifically, the drying extract of pumpkin seeds obtained by drying the alcohol (60 wt% ethanol) extract of Western pumpkin seeds in Germany, for example, is effective for overactive bladder (urinary, persecution urinary incontinence, residual urine), especially for women with urination disorders. It is known as Kommission E. monograph NO.11 / 199l.01.17.

In addition, studies have been made on the relationship between pumpkin seed components and action, and urinary action by linoleic acid has been clarified. (1990 Urologe [B] 3O: pages 62 to 66, Professor H. Schiloioher, Free University of Berlin, Urology HJ See Schneider).

An object of the present invention is to provide a urination disorder therapeutic agent having improved therapeutic effect by blending another component into the above known urination disorder therapeutic agent containing a dry extract of pumpkin seeds as an active ingredient.

As a result of earnestly examining in order to achieve the above object, the present inventors have found that the isoflavone which is present as a free or glycoside in various plants containing phytoestrogens has an effect of treating urination disorders containing dry extract of pumpkin seeds as an active ingredient. A surprising discovery was made that it is significantly improved.

This invention was completed based on the said discovery, The summary contains the dry extract and isoflavone of a pumpkin seed as an active ingredient, The blending ratio of the dry extract of a pumpkin seed: isoflavone is 99: 1-80:20 It is in the urination disorder therapeutic agent characterized by the weight ratio.

Hereinafter, the present invention will be described in detail. This invention improves the effect of the urination disorder therapeutic agent which contains the dry extract of a pumpkin seed as an active ingredient by using isoflavone together. Therefore, the kind of urination disorder therapeutic agent used as the base is not particularly limited as long as the active ingredient is a dry extract of pumpkin seeds.

In addition, the components of mature pumpkin seeds consist of about 1% by weight of sterols and steroglycosides, 35 to 53% by weight of fatty oils and fatty acids, 6 to 10% by weight of carbohydrates, and 4 to 6% by weight of fibers. In addition to linoleic acid as a fatty acid, tocopherol, phospholipids, tryptic protein, titerpene, squalene, carboxylic acid, cucklebitol, rare amino acids, carotenoids, kryptoxanthin, manganese, zinc, magnesium salts and the like are contained as microcomponents.

As a dry extract of pumpkin seeds, for example, alcohol (60% by weight) of dry extracts known in Germany as a therapeutic agent for urination disorders, that is, Western pumpkin seeds, particularly Cucurbita e pepo Linne seeds, as described above. Dry extract of the pumpkin seeds obtained by drying the ethanol) extract can be suitably used. Moreover, since the dry extract of such a pumpkin seed is marketed, for example by Ask Chemical Co., Ltd., it can be obtained easily.

Isoflavones, on the other hand, are compounds known to exist as free or glycosides in various plants containing phytoestrogens. As a plant containing phytoestrogens, it is a quinine fruit family; Beet, etc., Asteraceae; Sunflower etc., Brassicaaceae; Brassicaea et al., Euphorbiaaceae; Castor et al., Poaceae; Barley, wheat, rice, rye, etc. Lamiales; Sage et al., Leguminosae; Alfalfa, clover, soybean, Gaukurua, etc., Liliaceae; Garlic et al., Malvaceae; Holly Hock et al., Arecaceae; Yatsume coconut, etc. Edible rhubarb and the like, rosaceae: apples, cherry blossoms, apricots, etc., Rubiaceae; Willow, such as coffee; Willow et al., Solanaceae; Potatoes et al., Apiaceae; Parsley, etc. are mentioned.

In the present invention, in particular, isoflavones (so-called soybean isoflavones) extracted from soybean or gau croa are suitably used. This isoflavone has been noted for its excellent health effects by ingesting it through soybeans. Since isoflavones separated, concentrated, and purified from soybeans (mainly embryonic) are commercially available from, for example, Sangban Plant Chemical Research Institute, they can be easily obtained.

Although the urination disorder treatment agent of this invention contains the above-mentioned dry extract of pumpkin seed and isoflavone as an active ingredient, the blending ratio of the dry extract of a pumpkin seed: isoflavone becomes 99: 1-80:20 weight ratio.

When the blending ratio of isoflavone is less than the above range, the improvement of the therapeutic effect of isoflavone on the urination disorder therapeutic agent is not sufficiently expressed. On the other hand, when the blending ratio of isoflavone is larger than the above range, the dry extract content of the pumpkin seed, which is the original active ingredient as a urination disorder treatment agent, is lowered, so the effect of treating urination disorder is inferior.

The formulation of the therapeutic agent for treating urination disorders of the present invention may generally be a powder, granules, tablets because all of the above-mentioned active ingredients are available in powder form, but tablets are particularly preferred. In the case of tableting, conventionally well-known excipients and other additives can be used timely. Examples of excipients and other additives include malt dextrin, lactose (DMV), corn starch (cornstarch), (β-cyclo) dextrin, crystalline cellulose, and calmerose calcium.

Since the urination disorder treatment agent of the present invention is the same as the conventional known urination disorder treatment agent using dry extract of pumpkin seeds, except that a small amount of isoflavone is blended, the dosage is the same as that of the conventionally known It can be determined in the same manner as the treatment for urination disorder. Specifically, the amount of dry extract of pumpkin seeds is usually 500 mg, preferably 300 to 400 mg in 200 per day. Then, it is usually divided into three times and administered.

Example

Hereinafter, although an Example demonstrates this invention still in detail, this invention is not limited to a following example, unless the summary is exceeded.

Example 1 and Comparative Example 1

<Preparation of urination obstacle therapeutic agent>

From each component shown in Table 1, one tablet of 250 mg of the urination disorder treatment agent of the present invention was prepared according to a conventional method (Example 1). In addition, the weight of Table 1 is a numerical value with respect to 6 tablets.

Table 1

In Example 1, except for using the other components except soy isoflavones in the same manner as in Example 1 to prepare a comparative 250 mg urine therapeutic agent for l grains (Comparative Example 1).

<Effect of urination disorder therapeutic agent>

50 patients with frequent urination with at least three times of night urination were randomly divided into two groups of A and B of the same number, group A was administered the therapeutic agent for urination disorder of Example 1, and group B of Comparative Example 1 The treatment for urination disorder was administered. The dosage was either 2 tablets (6 tablets per day) in the morning, lunch, and dinner. And after the start of administration, the average number of days in the group was determined from the days of each patient whose number of nighttime urinations decreased by one. As a result, the average days were 4 days for the urination disorder treatment agent of Example 1, and the average days were 24 days for the urination disorder treatment agent of Comparative Example 1.

According to the present invention described above, an isoflavone is combined with a known urination disorder therapeutic agent containing a dry extract of pumpkin seeds as an active ingredient, thereby providing an improved urination disorder therapeutic agent.

Claims (4)

A therapeutic agent for treating urination disorder, comprising a dry extract of pumpkin seeds and isoflavones as an active ingredient, and a blending ratio of dry extract of pumpkin seeds: isoflavones in a range of 99: 1 to 80:20 weight ratio. The agent for treating urination disorders according to claim 1, wherein the dry extract of pumpkin seeds is obtained by drying an alcohol extract. The agent for treating urination disorder according to claim 1 or 2, wherein the pumpkin seed is a seed of Cucurbitae pepo Linne, which is a type of amber zucchini. The agent for treating urination disorders according to any one of claims 1 to 3, wherein the isoflavone extracted from soybean or gaucroa is used as isoflavone.